araag2/HINT huggingface dataset:
Clinical trial NCT00696878 (phase 3, status: completed)
Conditions: in vitro fertilization
ICD codes: N98.2
Drugs: corifollitropin alfa, progesterone
SMILES: [H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females of couples with an indication for COS and IVF or ICSI;

          -  >=18 and <=39 years of age at the time of signing informed consent;

          -  Body weight > 60 kg and body mass index (BMI) >=18 and <=29 kg/m^2;

          -  Normal menstrual cycle length: 24-35 days;

          -  Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is
             allowed);

          -  Willing and able to sign informed consent.

        Exclusion Criteria:

          -  History of or any current (treated) endocrine abnormality;

          -  History of ovarian hyper-response or history of ovarian hyperstimulation syndrome
             (OHSS);

          -  History of or current polycystic ovary syndrome (PCOS);

          -  More than 20 basal antral follicles (size: <11 mm, both ovaries combined) as measured
             on USS in the early follicular phase (menstrual cycle day 2-5);

          -  Less than 2 ovaries or any other ovarian abnormality, including endometrioma >10 mm
             (visible on USS);

          -  Presence of unilateral or bilateral hydrosalpinx (visible on USS);

          -  More than three unsuccessful COS cycles since the last established ongoing pregnancy
             (if applicable);

          -  History of non- or low ovarian response to FSH/human menopausal gonadotrophin (hMG)
             treatment;

          -  FSH > 12 IU/L or luteinizing hormone (LH) > 12 IU/L as measured by the local
             laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);

          -  Any clinically relevant abnormal laboratory value based on a sample taken during the
             screening phase, including abnormal cervical smear (Papanicolaou [PAP]>=III, cervical
             intraepithelial neoplasia [CIN]>=1);

          -  Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation,
             undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) or GnRH antagonists
             (e.g. hypersensitivity, pregnancy/lactation);

          -  Recent history of or current epilepsy, human immunodeficiency virus (HIV) infection,
             thrombophilia, diabetes or cardiovascular, gastro-intestinal, hepatic, renal, or
             pulmonary disease;

          -  Abnormal karyotyping of the participant or her partner (if karyotyping is performed);

          -  History or presence of alcohol or drug abuse within 12 months prior to signing
             informed consent;

          -  Previous use of corifollitropin alfa;

          -  Use of hormonal preparations within 1 month prior to screening;

          -  Administration of investigational drugs within three months prior to signing informed
             consent.
Clinical trial NCT00723411 (phase 3, status: terminated)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: rhgad65, rhgad65, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the primary endpoint at 15 months was not met.
  
Eligibility criteria:

        Main Inclusion Criteria:

          -  Male and female patients between 10 and 20 years of age

          -  Insulin dependent type 1 diabetes mellitus diagnosed within the previous 3 months at
             time of screening

          -  Fasting C-peptide level at time of screening above 0.1 nmol/L

          -  Elevated GAD65 antibodies (GADA) at time of screening

        Main Exclusion Criteria:

          -  Treatment with immunosuppressants or any anti-diabetic medications other than insulin

          -  A history of certain diseases or conditions (e.g. anemia, HIV, hepatitis, epilepsy,
             head trauma, neurological diseases or cerebrovascular accident, alcohol or drug abuse
             etc)

          -  Treatment with any vaccine within 1 month prior to planned first Diamyd dose or
             planned treatment with vaccine up to 2 months after the last injection with Diamyd,
             excluding the influenza vaccine

          -  Participation in other clinical trials with a new chemical entity within the previous
             3 months

          -  Pregnancy or planned pregnancy within 1 year after the last Diamyd dose

          -  Presence of associated serious disease or condition which in the opinion of the
             investigator makes the patient non-eligible for the study
Clinical trial NCT01079234 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin degludec, insulin glargine, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes for 12 months or longer, hereof the last 3 months with injection based
             therapies

          -  Current treatment with any basal insulin (e.g. insulin glargine, insulin detemir, NPH
             insulin) using one or two daily injections and with three or more daily meal-time
             insulin injections (e.g. insulin aspart, insulin lispro, insulin glulisine, human
             insulin) used as bolus insulin therapy

          -  HbA1c maximum 10.0 % by central laboratory analysis

          -  Body Mass Index (BMI) below or equal to 35.0 kg/m^2

          -  Ability to self-manage insulin therapy as assessed by confirmation (verbal
             confirmation at screening visit) of a changed insulin dose in the preceding two months
             prior to screening

          -  Ability and willingness to adhere to the protocol including performance of self
             measured plasma glucose (SMPG) profiles and self adjustment of insulin doses

        Exclusion Criteria:

          -  Use within the last 3 months prior to Visit 1 of any antidiabetic glucose lowering
             drug other than insulin

          -  Cardiovascular disease, within the last 6 months prior to visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/ untreated severe hypertension (systolic blood pressure above or
             equal to 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure above or
             equal to 100 mmHg)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements

          -  Cancer and medical history of cancer (except basal cell skin cancer or squamous cell
             skin cancer)
Clinical trial NCT00365300 (phase 3, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: pantoprazole, placebo
SMILES: COC1=C(OC)C(CS(=O)C2=NC3=C(N2)C=C(OC(F)F)C=C3)=NC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  term or post term infants beyond the neonatal period of an age greater than 28 days
             but less than or equal to 11 months

          -  clinical diagnosis of GERD

          -  weight greater than 2.5 kg and less than or equal to 15 kg

        Exclusion Criteria:

          -  known history of upper GI anatomic disorders

          -  history of acute life-threatening medical conditions

          -  clinically significant medical conditions or laboratory abnormalities
Clinical trial NCT01294423 (phase 3, status: completed)
Conditions: type 2 diabetes, high blood sugar
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Men or women age ≥20 years old (Either gender needs to be 40% or higher of total
             number of treated subjects)diagnosed with type 2 DM ; ≥6.5% and ≤10% at 1 week before
             randomization

        Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  FPG >240 mg/dL before randomization

          -  Subjects who have history of unstable or rapidly progressing renal disease

          -  Subjects who have severe hepatic insufficiency and/or significant abnormal liver
             function

          -  Significant cardiovascular history
Clinical trial NCT01557166 (phase 3, status: completed)
Conditions: metabolism and nutrition disorder, obesity, obstructive sleep apnoea
ICD codes: E70.5, E71.32, E72.4, E76.9, E78.89, E83.2, E88.40, E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211, G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  Body mass index equal to or above 30 kg/m^2

          -  Stable body weight (less than 5% self-reported change during the previous 3 months)

          -  Diagnosis of moderate or severe obstructive sleep apnoea (OSA)

          -  Unwilling or unable to use continuous positive airway pressure (CPAP) (or other
             positive airway pressure) treatment. No CPAP (or other positive airway pressure)
             treatment for at least four weeks prior to screening

          -  Ability and willingness to comply with all protocol procedures e.g. correct handling
             of trial product, compliance to visit schedule and dietary advice and complete trial
             related questionnaires

        Exclusion Criteria:

          -  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl
             peptidase-4 inhibitors or insulin within the last 3 months prior to screening

          -  Diagnosis of type 1 or type 2 diabetes per judgement of the investigator

          -  Glycosylated haemoglobin (HbA1c) equal to or above 6.5%

          -  Significant craniofacial abnormalities that may cause OSA

          -  Respiratory and neuromuscular diseases that could interfere with the results of the
             trial in the opinion of the investigator

          -  Use of central stimulants, hypnotics, mirtazepine, opioids, trazodone within the
             previous 3 months prior to screening

          -  Obesity induced by drug treatment

          -  Treatment with pramlintide, sibutramine, orlistat, zonisamide, topiramate or
             phenteremine within the last 3 month prior to screening

          -  Previous surgical treatment for obesity

          -  Screening calcitonin equal to or above 50 ng/L

          -  Familial or personal history of Multiple Endocrine Neoplasia type 2 or familial
             Medullary Thyroid Carcinoma

          -  Personal history of non-familial Medullary Thyroid Carcinoma

          -  History of chronic pancreatitis or idiopathic acute pancreatitis

          -  History of Major Depressive Disorder or suicide attempts

          -  Systolic blood pressure equal to or above 160 mmHg and/or diastolic blood pressure
             equal to or above 100 mmHg
Clinical trial NCT01642914 (phase 3, status: completed)
Conditions: chronic constipation, constipation
ICD codes: K59.04, K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: linaclotide 290 micrograms, linaclotide 145 micrograms, matching placebo
SMILES: [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, [H][C@]1(CSSC[C@]2([H])NC(=O)[C@H](CC3=CC=C(O)C=C3)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CSSC[C@H](N)C(=O)N3)NC2=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has completed a colonoscopy according to the American Gastroenterological
             Association criteria with no clinically significant findings

          -  Patient has successfully completed protocol procedures (with no clinically significant
             findings)

          -  Patient meets protocol criteria for Chronic Constipation(CC): < 3 bowel movements per
             week and reports one or more of the following symptoms for at least 12 weeks:

               1. Straining during more than 25% of BMs

               2. Lumpy or hard stools during more than 25% of BMs

               3. Sensation of incomplete evacuation during more than 25% of BMs

          -  Patient demonstrates continued chronic constipation and bloating through Pretreatment
             Period

          -  Patient is compliant with Interactive voice response System (IVRS)

        Exclusion Criteria:

          -  Patient has a history of loose or watery stools

          -  Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)

          -  Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease
             or condition that can affect GI motility

          -  Patient has any protocol-excluded or clinically significant medical or surgical
             history that would limit the patient's ability to complete or participate in this
             clinical trial or could confound the study assessments
Clinical trial NCT01257451 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  age: ≥ 70 years inclusive at Visit 1.

          -  patients with a confirmed diagnosis of T2DM

          -  HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the
             investigator to be inadequately controlled

          -  body mass index (BMI) in the range of 19-45kg/m2

        Exclusion Criteria:

          -  FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)

          -  previous or current participation in any vildagliptin clinical study.

          -  history of hypersensitivity to DPP-4 inhibitors.

          -  concurrent medical condition that may interfere with the interpretation of efficacy
             and safety data during the study.

          -  donation of blood or significant blood loss equaling to at least one unit of blood
             within the past 2 weeks of start of study or a blood transfusion within the past 12
             weeks or planned regular transfusions during the study period Other protocol-defined
             inclusion/exclusion criteria may apply
Clinical trial NCT00003771 (phase 3, status: completed)
Conditions: breast cancer, menopausal symptoms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: norethindrone acetate
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  History of stage 0-II breast cancer with no more than 4 involved axillary nodes if
             nodal status and number of nodes investigated is known

          -  No current evidence of disease

          -  Hormone receptor status:

               -  Positive, negative, or unknown

        PATIENT CHARACTERISTICS:

        Age:

          -  Not specified

        Sex:

          -  Female

        Menopausal status:

          -  Menopausal or perimenopausal

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  No active liver disease

        Renal:

          -  Not specified

        Cardiovascular:

          -  No prior or concurrent deep vein thrombosis

          -  No hereditary traits for deep vein thrombosis

          -  No prior or concurrent cerebral stroke

          -  No prior or concurrent coronary disease

        Other:

          -  No prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix

          -  No porphyria

          -  No other serious disease that would prevent compliance or greatly limit life
             expectancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  Prior hormone replacement therapy (HRT) allowed if stopped no more than 4 weeks after
             breast cancer diagnosis and at least 3 months prior to study

          -  No prior HRT initiated after breast cancer diagnosis

          -  No concurrent hormonal therapy for breast cancer except tamoxifen or toremifene

        Radiotherapy:

          -  No concurrent radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  No prior randomization into trials comparing effects of chemotherapy and bilateral
             oophorectomy in premenopausal women
Clinical trial NCT00191516 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: atomoxetine
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients who are at least 6 years of age and who will not have
             reached their 12th birthday

          -  Diagnosis of ADHD

          -  Normal intelligence

        Exclusion Criteria:

          -  Weigh less than 20 kg or more than 60 kg at study entry

          -  Other relevant psychiatric diagnoses

          -  Are at serious suicidal risk as determined by the investigator

          -  Have a history of severe allergies

          -  Alcohol or drug abuse within the past 3 months
Clinical trial NCT01076764 (phase 3, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: otamixaban, placebo (for otamixaban), ufh, placebo (for ufh), eptifibatide, placebo (for eptifibatide)
SMILES: COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

        Patient with non-ST-segment elevation Acute Coronary Syndrome (NSTE-ACS) with:

          1. Ischemic symptoms (chest pain or equivalent) at rest ≥ 10 minutes within 24 hours of
             randomization,

             AND

          2. One of the two following criteria:

               -  New ST-segment depression ≥ 0.1 mV (≥1 mm), or transient (< 30 minutes)
                  ST-segment elevation ≥ 0.1 mV (≥ 1 mm) in at least 2 contiguous leads on the
                  electrocardiogram,

               -  Elevation of cardiac biomarkers within 24 hours of randomization, defined as
                  elevated troponin T, troponin I, or CK-MB level above upper limit of normal,

             AND

          3. Planned to have a coronary angiography (followed, when indicated, by PCI) as early as
             possible (after at least 2 hours of treatment with study drug) and within 36 hours (at
             the latest on Day 3, if justified),

             AND

          4. Informed consent obtained in writing.

        Exclusion criteria:

          -  Revascularization procedure already performed for the qualifying event Acute
             ST-segment elevation MI.

          -  Patient having received curative dose of anticoagulant treatment (including UFH, LMWH,
             or bivalirudin) for more than 24 hours prior to randomization or who have been treated
             by abciximab.

          -  Inability to discontinue current anticoagulation in order to transition to
             Investigational Products according to the specified transition timing.

          -  Patient who can not be treated by aspirin and clopidogrel (or any other oral
             antiplatelet agent) according to their local labeling.

          -  Patient who cannot be treated with eptifibatide according to the national labeling
             (when available). In countries where eptifibatide is not approved the reference label
             to be considered is either the European labeling or the US labeling

          -  Patient who cannot be treated with unfractionated heparin according to the national
             labeling.

          -  Allergy to otamixaban.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01205126 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: hydromorphone hcl, oxycodone hcl cr, placebo
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O, CC(=O)OC1=CC=CC=C1C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants receiving strong oral or transdermal (through the skin) opioid analgesics
             with inadequate control of moderate to severe (very serious, life threatening) cancer
             pain or who presented with cancer pain and will be eligible to move to Step 3 of the
             WHO analgesic ladder when receiving weak opioids

          -  Participants who require or are expected to require between 40 mg and 184 mg of oral
             morphine or morphine equivalents every 24 hours for the chronic management of cancer
             pain

          -  Participants who are reasonably expected to achieve a stable dose of opioid study
             medication during the study

          -  Participants who are not expected to start a course of chemotherapy, radiotherapy,
             targeted cancer therapy, hormone therapy or diphosphates therapy after enrolment into
             the study. If participants are receiving long-term treatment including hormone
             therapy, target cancer therapy and diphosphate, the treatment should be kept stable as
             much as possible from 2 weeks before randomization and up to the completion of the
             study, encompassing the titration and maintenance phases

          -  Female participants who are premenarchal, postmenopausal, or surgically sterile,
             abstinent or if sexually active, they must use a medically acceptable method of
             contraception and must be willing to continue to use the same method of contraception
             throughout the study

        Exclusion Criteria:

          -  Participants with neuropathic pain or pain of unknown origin, or acute pain -
             Participants having pain only on movements

          -  Participants requiring other opioid analgesics (apart from morphine hydrochloride
             (HCl), in immediate release formulation, allowed as rescue medication for breakthrough
             pain)

          -  Participants with a recent history (within the previous 6 months) or current history
             of drug abuse or alcohol abuse

          -  Women of childbearing potential who were pregnant or lactating, seeking pregnancy or
             failing to use an adequate contraceptive method